GNLX — Genelux Corporation Common Stock

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Genelux Corporation Common Stock

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$3.06
Market Cap$131M
Float36.5M
Shares Outstanding44.8M
Price/Sales (TTM)16,366.75
vs. Analyst Target+471.9% to analyst PT
Operating Margin (TTM)-432112.50%
Revenue (TTM)$8,000
Dividend RateNone
Analyst Target Price$17.50 (5 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$14.9M -$658,000 -$11.8M
2021 N/A -$17.8M -$895,000 -$13.7M
2022 $11.1M -$5.2M $10.1M -$1.7M
2023 $170,000 -$28.3M -$848,000 -$26.5M
2024 $8,000 -$29.9M -$895,000 -$29.0M
2025 $8,000 -$32.1M -$566,000 -$32.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$7.5M
Sep 2025 N/A -$8.0M
Dec 2025 $8,000 -$9.2M
Mar 2026 N/A -$7.1M

Ownership & Float

Insider Ownership10.7%
Institutional Ownership30.7%
Short Float8.6%
% of All Funds Holding0.80%
Number of Funds Holding66

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$2.76Near-term / short-term trend
Weekly40-Week SMA$3.76Medium-term trend
Weekly80-Week SMA$3.45Cyclical trend (business cycle)
Weekly200-Week SMA$0.00Secular trend (multi-year)
Monthly10-Month SMA$3.93Near-term monthly trend
Monthly20-Month SMA$3.49Medium-term monthly trend
Monthly40-Month SMA$8.63Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.40 resistance 1.93x 3 months ago
$8.10 resistance 1.54x 5 months ago
$2.40 support 1.27x 15 months ago

Historical Earnings Reactions (14 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.46% 0.00% 42.86% 7.80% -4.31%
1 Day -7.25% -5.42% 14.29% 3.33% -32.40%
1 Week -8.31% -6.12% 21.43% 6.59% -29.72%
2 Weeks -9.00% -3.89% 35.71% 13.17% -40.82%
1 Month -6.93% -9.02% 42.86% 41.88% -41.96%

Next earnings: May 5, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.35% 47.8% 157
Tuesday 0.87% 46.2% 173
Wednesday 0.70% 48.8% 170
Thursday -0.06% 44.2% 165
Friday -0.42% 48.5% 169

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 30.7%

Insider Transactions — Smart Summary

Total insider ownership: 10.7%

12-Month Insider Activity Summary

Total Filings14
Net Value-$132,622.604
Net Shares Change-57,669
% of Float-0.2%
C-Suite Filings12
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
Zindrick Thomas President and CEO -$83,264.63 3 3 sell
Yu Yong Chief Scientific Officer -$20,022.828 3 3 sell
Cappello Joseph Chief Technical Officer -$3,991.911 2 2 sell
Smalling Ralph Head of Regulatory -$2,241.779 2 2 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-12-02 – 2025-12-11 5 5 -$155,511.971 4 C-suite
2026-03-26 – 2026-03-26 4 4 -$14,490.767 4 C-suite
2026-05-12 – 2026-05-12 4 4 -$12,627.866 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-12 Zindrick Thomas President and CEO -$8,225.56 Transaction at $2.94, now +4.1%
2026-05-12 Yu Yong Chief Scientific Officer -$1,798.423 Transaction at $2.97, now +2.9%
2026-05-12 Smalling Ralph Head of Regulatory -$804.492 Transaction at $2.98, now +2.7%
2026-05-12 Cappello Joseph Chief Technical Officer -$1,799.391 Transaction at $2.97, now +2.9%
2026-03-26 Zindrick Thomas President and CEO -$8,668.44 Transaction at $2.42, now +26.4%
2026-03-26 Yu Yong SVP, Clinical Development -$2,192.52 Transaction at $2.42, now +26.4%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Genelux Corporation Common Stock (GNLX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for GNLX on Trend Edge →